Bone and Parathyroid Strategies for Primary Care-Phosphatonins: From Discovery to Therapeutics

Video Transcription

Video Summary

Dr. Raj Kumar gave a talk on phosphatonins, hormones involved in phosphate transport, and their role in regulating phosphate homeostasis. He discussed various factors that can affect phosphorus concentrations, such as vitamin D metabolism, calcium and phosphate homeostasis, and tumor-induced osteomalacia. Dr. Kumar explained the role of FGF23, SFRP4, and MEPI in regulating phosphate transport. He showed that these substances cause phosphaturia and inhibit phosphate transport in the kidney. He also discussed the mechanisms by which they reduce phosphate reabsorption, including changes in the number of sodium phosphate co-transporters on renal tubular epithelial cells. Dr. Kumar highlighted the clinical conditions associated with alterations in phosphotonin levels, such as tumor-induced osteomalacia, X-linked hypophosphatemia, and autosomal dominant and autosomal recessive hypophosphatemic rickets. He mentioned that the administration of a monoclonal humanized antibody against FGF23, called Burosimumab, can be used to treat patients with tumor-induced osteomalacia and X-linked hypophosphatemia, resulting in an increase in serum phosphate concentrations and improvements in bone mineralization and fracture healing. Dr. Kumar also discussed the clinical approach to diagnosing and treating hypophosphatemia, including measuring various laboratory values and conducting skeletal investigations to locate any tumors responsible for the condition. Overall, his talk shed light on the importance of phosphatonins in regulating phosphate homeostasis and their potential therapeutic use in treating hypophosphatemia.

Keywords

phosphatonins

phosphate transport

phosphate homeostasis

FGF23

SFRP4

MEPI

phosphaturia

kidney

hypophosphatemia

Burosimumab